Logo

INMB

INmune Bio, Inc.

INMB

INmune Bio, Inc. • NASDAQ
$1.74 ▲ 5.45% (+0.09)
Market Cap $46.26 M
52w High $11.64
52w Low $1.38
Dividend Yield 0%
P/E -0.84
Volume 398.92K
Outstanding Shares 26.59M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $7.405M ▼ $-6.472M ▲ 0% $-0.24 ▲ $-6.444M ▲
Q2-2025 $0 ▼ $24.571M ▲ $-24.458M ▼ 0% ▲ $-1.05 ▼ $-8.057M ▲
Q1-2025 $50K ▲ $9.955M ▲ $-9.739M ▼ -19.478K% ▼ $-0.43 ▼ $-9.905M ▼
Q4-2024 $0 $9.467M ▼ $-9.218M ▲ 0% $-0.41 ▲ $-9.218M ▲
Q3-2024 $0 $12.286M $-12.093M 0% $-0.6 $-12.093M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $27.734M ▼ $33.358M ▼ $7.98M ▼ $25.378M ▼
Q2-2025 $33.374M ▲ $37.684M ▼ $8.817M ▲ $28.867M ▼
Q1-2025 $19.337M ▼ $37.801M ▼ $8.128M ▲ $29.673M ▼
Q4-2024 $20.922M ▼ $39.562M ▼ $7.465M ▼ $32.097M ▼
Q3-2024 $33.552M $52.782M $14.107M $38.675M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.472M ▲ $-5.439M ▲ $-193K ▲ $0 ▼ $-5.64M ▼ $-5.632M ▲
Q2-2025 $-24.458M ▼ $-7.375M ▼ $-706K ▼ $22.271M ▲ $14.037M ▲ $-8.081M ▼
Q1-2025 $-9.739M ▼ $-6.824M ▲ $0 $5.274M ▲ $-1.585M ▲ $-6.824M ▲
Q4-2024 $-9.218M ▲ $-11.013M ▼ $0 $-2.078M ▼ $-12.63M ▼ $-11.013M ▼
Q3-2024 $-12.093M $-6.986M $0 $9.792M $2.483M $-6.986M

Five-Year Company Overview

Income Statement

Income Statement INmune Bio is still a pure research company with no product revenue yet, which is normal for an early‑stage biotech. Its main costs are research and corporate expenses, leading to steady annual losses. Those losses have been fairly consistent over the last few years, not exploding higher, but also not narrowing in a meaningful way. This means the company remains in a classic “spend now for potential future payoff” phase, with profitability dependent entirely on eventual drug approvals or partnerships.

Balance Sheet

Balance Sheet The balance sheet is relatively small and simple, reflecting a lean clinical‑stage biotech. The company holds a modest cash balance and a limited base of other assets, with only a small amount of debt. Equity is the primary source of funding, which typically means reliance on past or future share issuances to pay for development. Overall, resources appear adequate for a small operation but not yet sized for large, late‑stage trials or commercialization without additional capital.

Cash Flow

Cash Flow Cash flow is consistently negative, driven by ongoing research and development spending and normal operating costs. The company is not investing heavily in physical assets; most cash outflow is tied directly to clinical work and overhead. Because no products are on the market, there is no offsetting inflow from sales, so the business depends on external financing to replenish cash. The pattern suggests a steady, predictable burn rate, but also underlines funding risk if capital markets or partnerships do not materialize when needed.

Competitive Edge

Competitive Edge INmune Bio operates in highly competitive areas—Alzheimer’s, oncology, and rare diseases—but its approach is clearly differentiated. It focuses on tuning the innate immune system rather than following the mainstream paths of amyloid‑targeting drugs in Alzheimer’s or complex cell engineering in oncology. Its selective targeting of inflammatory signals and in‑body activation of natural killer cells set it apart scientifically, supported by patent protection. However, it competes indirectly with much larger, well‑funded companies, so success will depend on producing convincingly better safety, efficacy, or convenience in trials and then securing strong partners.

Innovation and R&D

Innovation and R&D Innovation is the core of the story here. The company is advancing multiple first‑in‑class programs: a selective inflammation blocker for brain and cancer diseases, an in‑vivo NK cell activator for cancer, and a cell therapy for rare skin disorders. Its strategy is very science‑driven, using biomarkers and carefully chosen patient groups to increase the odds of clinical success. At the same time, mixed trial results in Alzheimer’s highlight the inherent uncertainty of drug development—further studies, regulatory feedback, and execution quality will be critical in proving that the technology can consistently translate into real‑world benefit.

Summary

INmune Bio is an early, high‑risk, research‑focused biotech with no commercial products yet and a straightforward pattern of ongoing losses and cash burn. Its financial profile is typical for a clinical‑stage company: modest assets, limited debt, reliance on equity and external funding, and negative cash flow tied mainly to R&D. The main attraction is not current financial strength but its differentiated science in innate immunity, neuroinflammation, and NK cell biology, backed by patents and a focused precision‑medicine mindset. The key questions ahead are whether the company can generate clearly positive, reproducible clinical results, navigate regulators effectively, and secure the partnerships or funding needed to move from promising science to sustainable, revenue‑generating products.

NEWS

November 18, 2025 · 8:00 AM UTC

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Read more

October 30, 2025 · 4:05 PM UTC

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

Read more

October 14, 2025 · 7:00 AM UTC

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

Read more